search
Back to results

Start TB Patients on ART and Retain on Treatment (START Study) (START)

Primary Purpose

Tuberculosis, HIV

Status
Completed
Phase
Not Applicable
Locations
Lesotho
Study Type
Interventional
Intervention
Combination Intervention Package
Standard of Care
Sponsored by
Columbia University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Tuberculosis focused on measuring Lesotho, TB, tuberculosis, HIV, antiretroviral therapy, ART, adherence, combination intervention package, retention

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Measurement Cohort Participant Inclusion Criteria:

  1. HIV-infected
  2. On TB treatment
  3. Initiating ART within 2 months of TB treatment initiation
  4. Aged 18 or older
  5. English- or Sesotho-speaking
  6. Capable of informed consent

Measurement Cohort Participant Exclusion Criteria:

  1. Children under age of 18
  2. Patients diagnosed with Multi Drug Resistant-TB (MDR-TB)

Key Informats: Three groups of key informats (KI) will be recruited.

  • Key Informants ART Early-Initiators Inclusion Criteria:

    1. A measurement cohort participant
    2. Initiaing ART within the first 8 weeks of TB treatment
  • Key Informants ART Non/Late-Initiators Inclusion Criteria:

    1. A measurement cohort participant
    2. did not initiate ART during TB treatment or initiating ART >= 2 months after TB treatment initiation
  • Key Informants Healthcare Workers Inclusion Criteria:

    1. Nurse or VHW working in a CIP clinic or VHW working in the community and affiliated with CIP clinic
    2. Aged 18 or older
    3. English- or Sesotho-speaking
    4. Capable informed consent

Sites / Locations

  • Koali Health Center
  • Maluti Hospital
  • St. Magdalena Health Center
  • Khubetsoana Health Center
  • Pilot Health Center
  • Berea Hospital
  • Good Shepherd Health Center
  • Holy Family Health Center
  • Kolojane Health Center
  • Sebedia Health Center
  • St. David Health Center
  • St. Theresa Health Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Other

Arm Label

CIP Participants

SOC Participants

Arm Description

Participants will receive the usual procedures (standard of care) for management of HIV-infected TB patients, and in addition the Combination Intervention Package (CIP) with the programmatic, structural, and psychosocial components.

Participants will receive the usual procedures (standard of care) for management of HIV-infected TB patients. TB and HIV services are fully integrated in a one-stop model, while at hospitals, ART is provided in the TB clinic for TB/HIV coinfected patients.

Outcomes

Primary Outcome Measures

Percentage of TB/HIV patients newly registered during period of observation who initiate ART during TB treatment
To examine ART initiation based on review of clinic registers.
Percentage of participants who attended 6 month clinic visit (within 1 month window) and reported ART use
To examine ART retention. Deaths and transfers will be considered not retained.
Participants with cure + treatment completion at end of TB treatment
To examine TB treatment success as defined by WHO, based on review of TB register and treatment cards.

Secondary Outcome Measures

Days from TB treatment initiation to date of ART initiation
To examine Time to ART initiation
Percentage of total prescribed doses ingested for ART
To examine ART adherence, averaged across medicines for each month of treatment, from the unannounced pill counts.
Change in CD4+ count
To examine change in CD4 count over 6 months (from initiation of TB treatment to 6 months later). Routine clinical CD4 test results will be used by study staff and no additional blood draw will be required.
Percentage of smear positive pulmonary TB cases that converted to smear negative after eight weeks of treatment
To examine sputum smear conversion
Percentage of total prescribed doses ingested for TB treatment
To examine TB treatment adherence, from unannounced pill counts.
Ratio of the incremental costs of the CIP to incremental effectiveness
To examine incremental cost-effectiveness of CIP (per ART initiation, retention, and TB treatment completion)

Full Information

First Posted
May 31, 2013
Last Updated
July 12, 2021
Sponsor
Columbia University
Collaborators
United States Agency for International Development (USAID)
search

1. Study Identification

Unique Protocol Identification Number
NCT01872390
Brief Title
Start TB Patients on ART and Retain on Treatment (START Study)
Acronym
START
Official Title
Start TB Patients on ART and Retain on Treatment: Combination Intervention Package to Enhance Antiretroviral Therapy Uptake and Retention During TB Treatment in Lesotho
Study Type
Interventional

2. Study Status

Record Verification Date
July 2021
Overall Recruitment Status
Completed
Study Start Date
April 2013 (Actual)
Primary Completion Date
January 2016 (Actual)
Study Completion Date
May 7, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Columbia University
Collaborators
United States Agency for International Development (USAID)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the START Study is to identify an effective, cost-effective, acceptable intervention that addresses programmatic, structural and psychosocial barriers to ART initiation and retention during TB treatment, with the ultimate goal of improving health outcomes among HIV-infected TB patients in Lesotho. The study is a two-arm cluster randomized trial, randomized at the TB/HIV clinic level, which includes twelve TB/HIV clinics in Berea district. Clinics are randomized to deliver the combination intervention package (CIP) or standard of care (SOC), with stratification by facility type. The experimental intervention will be delivered to all HIV-infected TB patients in TB/HIV clinics randomly assigned to CIP. In TB/HIV clinics assigned to SOC, usual care procedures for ART initiation and retention will be delivered. Study hypotheses focus on the effectiveness of the CIP on HIV- and TB-related outcomes. Compared to HIV-infected TB patients attending SOC clinics, HIV-infected TB patients at CIP clinics will have superior HIV- and TB-related outcomes, including: Greater ART initiation during TB treatment Shorter time to ART initiation Greater retention in ART care Higher adherence to ART Greater change in CD4+ count Greater TB treatment success (completion and cure) Greater sputum smear conversion Higher adherence to TB treatment Additionally, CIP delivery will have an incremental cost-effectiveness ratio more favorable than alternative resource uses.
Detailed Description
Among people living with HIV (PLWH), tuberculosis (TB) is the most common opportunistic illness and a leading cause of death, accounting for nearly a quarter of HIV-related deaths worldwide. Initiating antiretroviral therapy (ART) early during TB treatment significantly increases survival, and World Health Organization (WHO) guidelines recommend ART initiation for all PLWH as soon as possible after TB treatment initiation, regardless of CD4+ count. Yet in the African Region, only 42% of TB patients known to be living with HIV were on ART in 2010, and retention in ART programs has been limited. In Lesotho, only 27% of HIVinfected TB patients received ART in 2010. There is an urgent need to identify programmatic interventions that increase the proportion of HIV-infected TB patients on ART, shorten the duration between TB diagnosis and ART initiation, and improve adherence to medications and retention in care amongst HIV-infected TB patients in Lesotho. Lesotho, a small, landlocked country completely surrounded by South Africa, is among the world's poorest nations with one of the world's most severe epidemics of HIV and tuberculosis (TB). There is strong evidence that TB patients who are also infected with HIV have better survival rates if they begin antiretroviral therapy (ART) soon after starting TB treatment; however, there are many patients who do not initiate ART within the recommended timeframe, and who do not remain in care.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tuberculosis, HIV
Keywords
Lesotho, TB, tuberculosis, HIV, antiretroviral therapy, ART, adherence, combination intervention package, retention

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
415 (Actual)

8. Arms, Groups, and Interventions

Arm Title
CIP Participants
Arm Type
Experimental
Arm Description
Participants will receive the usual procedures (standard of care) for management of HIV-infected TB patients, and in addition the Combination Intervention Package (CIP) with the programmatic, structural, and psychosocial components.
Arm Title
SOC Participants
Arm Type
Other
Arm Description
Participants will receive the usual procedures (standard of care) for management of HIV-infected TB patients. TB and HIV services are fully integrated in a one-stop model, while at hospitals, ART is provided in the TB clinic for TB/HIV coinfected patients.
Intervention Type
Other
Intervention Name(s)
Combination Intervention Package
Other Intervention Name(s)
CIP
Intervention Description
CIP will contain programmatic, structural and psychosocial components including: 1) nurse training and mentorship in TB/HIV cotreatment using a clinical algorithm; 2) reimbursement of transportation costs to monthly clinic visits for patients and treatment supporters; 3) health education using a TB and HIV treatment literacy curriculum for patients and treatment supporters; and 4) real-time adherence support using short message service (SMS) text messaging and trained village health workers (VHW). These components were selected for their promise, practicality, and feasibility of implementation and scale-up in HIV programs in diverse settings - in addition to SOC.
Intervention Type
Other
Intervention Name(s)
Standard of Care
Other Intervention Name(s)
SOC
Intervention Description
Usual procedures for management of HIV-infected TB patients will be followed: Three I's training, ART provision to TB patients in integrated clinics, and treatment supporter for TB treatment.
Primary Outcome Measure Information:
Title
Percentage of TB/HIV patients newly registered during period of observation who initiate ART during TB treatment
Description
To examine ART initiation based on review of clinic registers.
Time Frame
Up to 9 months
Title
Percentage of participants who attended 6 month clinic visit (within 1 month window) and reported ART use
Description
To examine ART retention. Deaths and transfers will be considered not retained.
Time Frame
Up to 6 months after TB treatment initiation
Title
Participants with cure + treatment completion at end of TB treatment
Description
To examine TB treatment success as defined by WHO, based on review of TB register and treatment cards.
Time Frame
Up to 9 months
Secondary Outcome Measure Information:
Title
Days from TB treatment initiation to date of ART initiation
Description
To examine Time to ART initiation
Time Frame
Up to 9 months
Title
Percentage of total prescribed doses ingested for ART
Description
To examine ART adherence, averaged across medicines for each month of treatment, from the unannounced pill counts.
Time Frame
Up to 9 months
Title
Change in CD4+ count
Description
To examine change in CD4 count over 6 months (from initiation of TB treatment to 6 months later). Routine clinical CD4 test results will be used by study staff and no additional blood draw will be required.
Time Frame
Up to 6 months after initial CD4 count
Title
Percentage of smear positive pulmonary TB cases that converted to smear negative after eight weeks of treatment
Description
To examine sputum smear conversion
Time Frame
Up to 8 weeks from initiation of TB treatment
Title
Percentage of total prescribed doses ingested for TB treatment
Description
To examine TB treatment adherence, from unannounced pill counts.
Time Frame
Up to 9 months
Title
Ratio of the incremental costs of the CIP to incremental effectiveness
Description
To examine incremental cost-effectiveness of CIP (per ART initiation, retention, and TB treatment completion)
Time Frame
Up to 2 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Measurement Cohort Participant Inclusion Criteria: HIV-infected On TB treatment Initiating ART within 2 months of TB treatment initiation Aged 18 or older English- or Sesotho-speaking Capable of informed consent Measurement Cohort Participant Exclusion Criteria: Children under age of 18 Patients diagnosed with Multi Drug Resistant-TB (MDR-TB) Key Informats: Three groups of key informats (KI) will be recruited. Key Informants ART Early-Initiators Inclusion Criteria: A measurement cohort participant Initiaing ART within the first 8 weeks of TB treatment Key Informants ART Non/Late-Initiators Inclusion Criteria: A measurement cohort participant did not initiate ART during TB treatment or initiating ART >= 2 months after TB treatment initiation Key Informants Healthcare Workers Inclusion Criteria: Nurse or VHW working in a CIP clinic or VHW working in the community and affiliated with CIP clinic Aged 18 or older English- or Sesotho-speaking Capable informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrea A Howard, MD
Organizational Affiliation
Columbia University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Koali Health Center
City
Koali
Country
Lesotho
Facility Name
Maluti Hospital
City
Mafeteng
Country
Lesotho
Facility Name
St. Magdalena Health Center
City
Mafeteng
Country
Lesotho
Facility Name
Khubetsoana Health Center
City
Maseru
Country
Lesotho
Facility Name
Pilot Health Center
City
Maseru
Country
Lesotho
Facility Name
Berea Hospital
City
Teyateyaneng
Country
Lesotho
Facility Name
Good Shepherd Health Center
City
Teyateyaneng
Country
Lesotho
Facility Name
Holy Family Health Center
City
Teyateyaneng
Country
Lesotho
Facility Name
Kolojane Health Center
City
Teyateyaneng
Country
Lesotho
Facility Name
Sebedia Health Center
City
Teyateyaneng
Country
Lesotho
Facility Name
St. David Health Center
City
Teyateyaneng
Country
Lesotho
Facility Name
St. Theresa Health Center
City
Teyateyaneng
Country
Lesotho

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Start TB Patients on ART and Retain on Treatment (START Study)

We'll reach out to this number within 24 hrs